Researchers at the Lewis Katz School of Medicine at Temple University (LKSOM), in collaboration with scientists at the University of Cambridge, have demonstrated that choline is an endogenous activator of sigma-1 receptors, an important advance in cell biology. Sigma-1 receptors are targets on psychoactive drugs that are commonly abused. Eugen Brailoiu, MD, Adjunct Associate Professor at the Center for Substance Abuse Research (CSAR) at LKSOM, is the study’s lead author and Mary E. Abood, PhD, Professor of Anatomy and Cell Biology at LKSOM and CSAR Professor, is co-author. The findings were published online in the journal Cell Reports and then picked up by ScienceDaily, Scienmag, Phys.org and Technology Networks.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH